ELI LILLY AND COMPANY Severance Costs (Deprecated 2013-01-31)
ELI LILLY AND COMPANY (LLY) reported Severance Costs (Deprecated 2013-01-31) of $74.50 million for the 12-month period ending 2012-12-31, per its 10-K filed 2013-02-21.
Discontinued › Expense Statement › Operating Expenses
us-gaap:SeveranceCosts · last filed 2013-02-21
- ELI LILLY AND COMPANY severance costs (deprecated 2013-01-31) for fiscal 2012 was $74.50M, a 70.41% decline from fiscal 2011.
- ELI LILLY AND COMPANY severance costs (deprecated 2013-01-31) for fiscal 2011 was $251.80M, a 77.32% increase from fiscal 2010.
- ELI LILLY AND COMPANY severance costs (deprecated 2013-01-31) for fiscal 2010 was $142.00M, a 43.43% increase from fiscal 2009.
- ELI LILLY AND COMPANY severance costs (deprecated 2013-01-31) for fiscal 2009 was $99.00M, a 26.12% decline from fiscal 2008.
| Period end | Severance Costs (Deprecated 2013-01-31) 12 month |
|---|---|
| 2012-12-31 | $74.50M 10-K · filed 2013-02-21 |
| 2011-12-31 | $251.80M 10-K · filed 2013-02-21 |
| 2010-12-31 | $142.00M 10-K · filed 2013-02-21 |
| 2009-12-31 | $99.00M 10-K · filed 2012-02-24 |
| 2008-12-31 | $134.00M 10-K · filed 2011-02-22 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Akari Therapeutics Plc (AKTX) | $1,527.991B | -47,921.42 | |
| JOHNSON & JOHNSON (JNJ) | United States | $652.528B | 29.10 |
| AbbVie Inc. (ABBV) | United States | $468.180B | 70.37 |
| Merck & Co., Inc. (MRK) | United States | $365.215B | 99.96 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |